GenesisCare, Prelude partner on breast cancer test

By LabPulse.com staff writers

February 24, 2021 -- GenesisCare and Prelude have partnered on an early-stage breast cancer test for women diagnosed with ductal carcinoma in situ (DCIS) or stage 0 cancer and who are being treated with breast-conserving surgery.

Developed by Prelude, the DCISionRT test assesses a woman's 10-year risk of recurrence of DCIS or the development of invasive breast cancer. The test provides predictive information regarding recurrence risk, allowing physicians to better select those patients who will benefit from radiation therapy and surgery.

The new partnership makes the test available in Australia and increases patient access in the U.S. through GenesisCare's cancer treatment centers.


Copyright © 2021 LabPulse.com
 

To read this and get access to all of the exclusive content on LabPulse.com, create a free account or sign in now.

Member Sign In:
MemberID or email address:  
Do you have a LabPulse.com password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?